Down-regulation amyloid β-protein 42 production by interfering with transcript of presenilin 1 gene with siRNA

Acta Pharmacologica Sinica

Volumn 25, Issue 12, 2004, Pages 1613-1618

  Luo, Huan Min ^a   Deng, Hui ^a   Xiao, Fei ^a   Gao, Qin ^a   Weng, Wen ^a   Zhang, Pei Fen ^a   Li, Xiao Guang ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Alzheimer disease; Amyloid beta protein; Amyloid beta protein precursor; Presenilin 1; RNA interference; Secretase; Small interfering RNA

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; DOUBLE STRANDED DNA; GAMMA SECRETASE; MUTANT PROTEIN; PRESENILIN 1; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA LIBRARY; DNA SEQUENCE; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSED SEQUENCE TAG; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; NONHUMAN; PLASMID; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SILENCER ELEMENT; TIME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; CHO CELLS; CRICETINAE; CRICETULUS; DOWN-REGULATION; ENDOPEPTIDASES; HUMANS; MEMBRANE PROTEINS; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 10344247680     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sambamurti K, Hardy J, Refolo LM, Lahiri DK. Targeting APP metabolism for the treatment of Alzheimer's disease. Drug Dev Res 2002; 56: 211-27.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
3. Pinnix I, Musunuru U, Tun H, Sridharan A, Golde T, Eckman C, et al. A novel γ-secretase assay based on detection of the putative C-terminal fragment-γ of amyloid β protein precursor. J Biol Chem 2001; 276: 481-7.
4. Struhl G, Adachi A. Nuclear access and action of notch in vivo. Cell 1998; 93: 649-60.
5. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398: 518-22.
6. De Strooper B, Annaert W. Where Notch and Wnt signaling meet. The presenilin hub. J Cell Biol 2001; 152: F17-20.
7. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, et al. The role of presenilin cofactors in the γ-secretase complex. Nature 2003; 422: 438-41.
8. Mark S. Duxbury MA, Edward E. Whang MD. RNA interference: a practical approach. J Surg Res 2004; 117: 339-44.
9. Omi K, Tokunaga K, Hohjoh H. Long-lasting RNAi activity in mammalian neurons. FEBS Lett 2004; 558: 89-95.
10. Schütze N. At the cutting edge: siRNA technology. Mol Cell Endocrinol 2004; 213: 115-9.
11. Wolfe MS, Citron M, Diehl TS, Xia W, Donkor IO, Selkoe DJ. A substrate-based difluoro ketone selectively inhibits Alzheimer's γ-secretase activity. J Med Chem 1998; 41: 6-9.
12. Lahiri DK, Farlow MR, Greig NH, Sambamurti K. Current drug targets for Alzheimer's disease treatment. Drug Dev Res. 2002; 56: 267-81.
13. Jain KK. RNAi and siRNA in target validation. Drug Discov Today 2004; 9: 307-9.
14. Sioud M. Therapeutic siRNAs. Trends Pharmacol Sci 2004; 25: 22-8.